Genetic and epigenetic aspects of depression and somatic disorders comorbidityon and somatic disorders comorbidity
https://doi.org/10.31363/2313-7053-2019-4-1-78-79
Abstract
Complicated cascade of shared biological components with a genetic basis and, probably, common triggers of the genetically posed risk are involved in the comorbidity of depressive symptoms and somatic disorders. This suggests that, under certain conditions, it can manifest both a single disease and a cluster of disorders with different phenomenological characteristics, united by common genetically mediated pathophysiological mechanisms. Based on the analysis of epidemiological, clinical, pathophysiological and genetic studies, we substantiated the hypothesis of cluster genetic comorbidity of depression and somatic diseases.
About the Authors
G. V. Rukavishnikov
Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
G. E. Mazo
Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
N. G. Neznanov
Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
A. O. Kibitov
Bekhterev National Medical Research Center for Psychiatry and Neurology; Serbsky National Medical Research Center on Psychiatry and Addictions
Russian Federation
Russian Federation
References
1. Neznanov NG, Mazo GE., Rukavishnikov GV, Kibitov AO. Depressija kak prediktor somaticheskih zabolevanij: patofiziologicheskie predposylki i geneticheskij risk. Uspehi fiziologicheskih nauk. 2017;48(4):29-39. (In Russ.).
2. Neznanov NG, Mazo GЕ., Rukavishnikov GV, Kibitov AO. Prognosticheskaja rol’ depressii v kachestve prediktora manifestacii hronicheskih somaticheskih zabolevanij. Terapevticheskij arhiv. 2018;90(12):122 — 132. (In Russ.).
3. Acharya T, Acharya S, Tringali S, Huang J. Association of antidepressant and atypical antipsychotic use with cardiovascular events and mortality in a veteran population. Pharmacotherapy 2013;33:1053–1061 4. Amare AT, Schubert KO, Klingler-Hoffmann M, Cohen-Woods S, Baune BT. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry. 2017;7(1):e1007. doi:10.1038/tp.2016.261
4. Brieler JA, Lustman PJ, Scherrer JF, Salas J, Schneider FD. Antidepressant medication use and glycaemic control in co-morbid type 2 diabetes and depression. Fam Pract 2016;33:30–36
5. Hollands G.J., French D.P., Griffin S.J., Prevost A.T., Sutton S., King S., Marteau T.M. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ. 2016;352:i1102. doi:10.1136/bmj.i1102
Review
For citations:
Rukavishnikov G.V., Mazo G.E., Neznanov N.G., Kibitov A.O. Genetic and epigenetic aspects of depression and somatic disorders comorbidityon and somatic disorders comorbidity. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2019;(4-1):78-79. (In Russ.) https://doi.org/10.31363/2313-7053-2019-4-1-78-79
Views:
984
Email this article 